Exemestane
Aromasin · Aromatase inhibitor (irreversible)
What it is
A steroidal aromatase inhibitor (it permanently disables the enzyme molecules it binds) used in breast cancer; it also circulates in AAS contexts.
What human evidence shows
Oncology evidence is solid. Claims of a gentler profile than other aromatase inhibitors, or of no estrogen rebound on stopping, are sometimes made on mechanistic grounds but are not established in non-medical use.
Risks
Same overshoot syndrome as every aromatase inhibitor (suppressed estrogen: libido, joints, mood, lipids, bone). An androgenic metabolite has been described, with uncertain clinical significance. Chronic low estrogen in men is a documented path to osteoporosis regardless of which molecule caused it.
Legal status
US: prescription-only. Products outside licensed dispensing are unapproved.
Evidence base
established literature
Large human evidence base: several phase 3 or 4 trial reports, plus multiple meta-analyses or systematic reviews.
- phase 3/4
- 93
- randomised
- 234
- reviews
- 63
- human trials
- 321
Counts are of published papers, not distinct trials, and measure how much research exists — not whether this works or is safe for you.
Research (12)
- Exemestane2012
- Exemestane2006
- ExemestaneDrugs · 1999
- Exemestane-Associated Bilateral MaculopathyJAMA Ophthalmol · 2025
- Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent EvidenceAdv Ther · 2022
- Exemestane: a novel aromatase inactivator for breast cancerClin Breast Cancer · 2000
- Exemestane (FCE 24304), a new steroidal aromatase inhibitorJ Steroid Biochem Mol Biol · 1992
- Unravelling exemestane: From biology to clinical prospectsJ Steroid Biochem Mol Biol · 2016
- Exemestane: a review of its use in postmenopausal women with advanced breast cancerDrugs · 2000
- Everolimus in postmenopausal hormone-receptor-positive advanced breast cancerN Engl J Med · 2012
- Exemestane in advanced breast cancerAnticancer Drugs · 2000
- Exemestane in postmenopausal women with early or advanced breast cancer: a reviewExpert Opin Pharmacother · 2010
Turn Exemestane into a plan that's yours
The info above is free. Membership makes it personal, the Coach answers questions about your exact stack, the Stack tracks it for you, and the Verified Sources shows you how to vet what you buy.
- ✓ AI Coach, ask anything about your stack. It does the dosing math, flags interactions, and tells you what to do next.
- ✓ Personal Stack, save your protocol, track it across devices, log doses, get a heads-up before a vial runs out.
- ✓ Verified Sources, the vetted reference for checking quality and sourcing, members only.
Cancel anytime · or save with $59.99/yr · Coach + Stack included